title: Hospitals should keep methylene blue.
authors.forename: Erik M
authors.initials: EM
authors.lastname: Hernandez
authors.forename: Joseph
authors.initials: J
authors.lastname: Rella
authors.forename: Bruce
authors.initials: B
authors.lastname: Ruck
authors.forename: Steven
authors.initials: S
authors.lastname: Marcus
mesh_terms: D000931:Antidotes / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D004396:Coloring Agents / Q000633:toxicity; D004750:Enteral Nutrition / Q000009:adverse effects; D004865:Equipment and Supplies, Hospital / Q000592:standards; D005572:Formularies, Hospital as Topic; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008706:Methemoglobin / Q000037:antagonists & inhibitors / Q000378:metabolism; D008708:Methemoglobinemia / Q000188:drug therapy / Q000209:etiology; D008751:Methylene Blue / Q000009:adverse effects / Q000627:therapeutic use*; D009515:New Jersey; D011039:Poison Control Centers; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000931:Antidotes; D001557:Benzenesulfonates; D004396:Coloring Agents; D006454:Hemoglobins; D008706:Methemoglobin; C006796:brilliant blue; D008751:Methylene Blue